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Malaria is the most common and lethal parasitic disease worldwide with an estimated 216 million 
of cases and 445,000 deaths in 2016 [1]. In Europe, where the disease has been eradicated malaria 
was  responsible of over 8000 imported cases in 2015,  two-thirds of which reported in France, the 
United Kingdom, Italy, Spain and Germany. The aim of this retrospective study was to describe the 
epidemiological and clinical characteristics of the imported malaria cases observed in Milan in the 
period 2010-2015. In addition, we compared it with those described in other recently published 
European studies [2-10]..   
During the study period, 180 cases of malaria were diagnosed in 177 patients (124 males, 70.1%, 
and 53 females, 29.9%). Their median age was 38 years (IQR 29-49); 117 (66%) were aged <45 
years. Sixty-three (35.6%) were Italian citizens, seven European citizens, and 107 (60.5%) extra-
European citizens (all originating from Africa except for five patients from Pakistan, two each from 
India and Brazil, and one from Thailand). The African patients (97, 54.8%) originated from 
eighteen countries, with Eritrea (20, 20.6%), Senegal (18, 18.6%), Nigeria (12, 12.4%) and the 
Ivory Coast (9, 9.3%) being the most represented. 
The average annual number of cases diagnosed at our hospital during the study period was 30, with 
the highest number of cases (40) in 2015 and the lowest in 2011 and 2012 (22). Cases were 
diagnosed in every month of the year, with peaks in September and October (32 cases each, 35.5%). 
Fifty-seven patients (32%) were classified as VFRs; 34 (19%) as immigrants, 51 (28.8%) as people 
travelling for working reasons and 20 (11%) for tourism; fifteen (9%) were expatriates, missionaries 
or people working in non-governmental organisations. 
The median duration of travel for tourism was 14 days, which was significantly shorter than the 33 
day spent in malaria-endemic areas by VFRs (p=0.001). Malaria was caused by P. falciparum alone 
in 136 cases (75.5%), P. vivax alone in 30 cases (16.7%), P. ovale alone in seven cases (3.9%), and 
P. malariae alone in four cases (2.2%). There were three cases of mixed infections (1.7%) caused 
by P. falciparum + P. vivax. All but one of the episodes of malaria due to P. falciparum alone were 
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acquired in Africa with West Africa (98, 72.1%) being the most frequent travel destination or place 
of origin. The distribution of the areas in which P. vivax malaria was acquired was more 
widespread, with the highest number occurring in Eritrea (16, 53.3%) and the Indian subcontinent 
(7, 23.3%). All of the cases of P. ovale and P. malariae were acquired in Africa .The median time 
from presentation at the Emergency Department (ED) of our hospital and parasitological diagnosis 
of malaria was three hours (IQR 2-5 hours), and the median time between the parasitological 
diagnosis and the start of antimalarial therapy was also three hours (IQR 1-4.1 hours). 
Severe P. falciparum malaria  (in one case associated with P. vivax) requiring Intensive Care Unit 
(ICU) admission was diagnosed in 12 patients (6.6%);  five more patients (2.8%) managed outside 
the ICU fulfilled the criteria for severe malaria: 2 hyperparasitaemia, 2 jaundice (with parasitaemia 
> 100,000/uL) and one hypotension. All of the other episodes were classified as uncomplicated 
malaria. The most common symptoms at the time of diagnosis were fever (174, 96.6%), headache 
(87, 49%), arthralgia/myalgia (74, 41.1%) and chills (71, 40%); gastrointestinal symptoms were less 
frequent: nausea in 36 cases (20%), vomiting in 42 cases (23%), diarrhea in 32 cases (18%), and 
abdominal pain in 19 cases (10.5%). 
The use of chemoprophylaxis was recorded for only 18 patients (10%), but was considered 
appropriate in 14 cases (73.7%). Thrombocytopenia was the most frequent hematologic alteration 
(observed in 79% of the cases), with a median value of 93,500/L (IQR 54,000-142,750/L). There 
was no difference in the prevalence of thrombocytopenia between the patients with P. falciparum 
malaria and those with P. vivax malaria (78.6% vs 73.3%). Anemia was detected in 48 cases 
(26.6%), but was statistically significantly more frequent among the patients with P. vivax malaria 
than among those with P. falciparum malaria (53.3% vs 19.1%, p<0.0001). Severe anemia (Hb 7 
g/dL) was detected upon admission in only three patients: two with P. falciparum malaria and one 
with P. vivax malaria. Forty-nine patients (27.4%) presented leukopenia, with a median value of 
5080/L (IQR 3835-6770/L).  
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The most frequent laboratory alterations were high serum lactate dehydrogenase levels (> 220 U/L) 
(112 cases, 62.2%) and increased bilirubin levels in 94 cases ( 52.5%) of whom 24 cases (13.3%) 
had levels above the 3 mg/dl. The median parasitaemia value in the case of P. falciparum malaria 
was 42,900/L (IQR  9,058-106,750), with 26 patients (20.5%) having a parasite count of 
>100,000/L ( excluding 10 patients with severe malaria admitted to the ICU  the remaining cases 
involved semi-immune African patients). The median P. vivax parasitaemia value was 8,290/L 
(IQR 1,867.25-45,750), with one patient having a parasite count of >100,000/L.  
One hundred and two blood samples (56.6%) taken at the time of diagnosis were concurrently  
tested with the immunochromatographic test (RDT, Core malaria Pan/PV/PF, CORE Diagnostics, 
Birmingham, UK) with the following positive results: P. falciparum 75/75 (100%), P. vivax 15/20 
(75%), P. ovale 0/5 (0%) and P. malariae 0/2 (0%), for an overall sensitivity of 88.2%. 
All of the patients were hospitalised regardless of the infecting Plasmodium species, and treatment 
was received in 179 cases (99.4%: one patient with P. vivax malaria abandoned the hospital before 
starting any treatment).  
The patients with P. falciparum malaria were most frequently treated with mefloquine (34.1%) and 
dihydroartemisinin-piperaquine (30.4%), which became the drug of choice for the treatment of 
uncomplicated P. falciparum malaria in our internal guidelines when it was registered in Italy in 
2013; quinine (alone or in combination with doxycycline) was used in 44 cases (24.6%). 
Chloroquine was most frequently used to treat non-falciparum malaria (80.5%).  
Parasite clearance was faster in the patients with uncomplicated P. falciparum malaria treated with 
dihydroartemisinin-piperaquine (a median of 43.75 hours) than in those treated with mefloquine (63 
hours) or quinine (72 hours) (p< 0.0001), but there was no statistically significant difference in 
defervescence time.  
The median duration of hospitalisation was shorter in the case of the patients treated with 
mefloquine (4 days, IQR 3-5 days) or dihydroartemisinin-piperaquine (4 days, IQR 3-5 days) than 
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among those treated with quinine (7 days, IQR 4-7 days; p<0.01). Outcomes were favourable in all 
cases, and relapses occurred in only two patients (one with P. vivax and the other with P. ovale  
malaria), neither of whom was treated with primaquine. 
VFRs are still the most affected risk group (32%), although the percentage is less than that reported 
in Spain and the UK [3-5] but also lower than that observed in other studies most of which 
performed in Italy [8-10]  (Table 1). Nineteen percent of our cases involved recent immigrants, 
most of whom were young refugees from Eritrea infected with P. vivax. 
We are not aware of any study of imported malaria that has recorded the time between a patient’s 
arrival at an Emergency Department (ED) and the subsequent parasitologic diagnosis of malaria or 
the time between diagnosis and the start of antimalarial treatment, although these are possible 
indicators of good and efficient clinical practice. In our case, these times were both very short (a 
median of 3 hours), possibly because our ED staff always includes a specialist in infectious 
diseases, an organisational condition that, to the best of our knowledge, does not exist at other 
Italian hospitals. The frequency of severe falciparum malaria varies widely in the European studies 
cited above (from 4.6% in Spain to 36.3% in UK) possibly because of the different criteria for 
severe malaria adopted [3-10].  The determination of HIV serology is recommended in febrile 
tropical travellers, but the findings of three recent studies from Spain and the UK indicate that 
compliance with this recommendation is only 27-48% [3-5]. We established the HIV serostatus of 
83% of our patients (147/177) at the time of the diagnosis of malaria, and found that 1.4% were 
HIV positive, which is less than the 8.9% prevalence observed in Fuenlabrada, Spain [4]. Given the 
large number of patients diagnosed with malaria originating from sub-Saharan Africa, and the 
possible negative effect of HIV on malaria outcomes, HIV serology should  be offered to all  
patients and test monitoring should be considered an indirect index of the quality of care. 
The immunochromatographic test used in our study had an overall sensitivity of 88.2% and, as 
expected, only performed satisfactorily in the case of  P. falciparum malaria  thus confirming that 
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an RDT should always be coupled with a blood smear examination in settings in which malaria is 
not endemic.  
In comparison with our previous study [2], there was a considerable decrease in the use of 
mefloquine (from 71.9% to 34.1%) to  treat uncomplicated falciparum malaria, and a parallel  
increase in the use of dihydroartemisinin-piperaquine (DHA-PPQ), the only artemisinin 
combination therapy (ACT) registered in Italy. We found that parasite clearance was faster in the 
patients receiving ACT than in those receiving mefloquine or quinine, and the duration of 
hospitalisation was shorter than in the case of those treated with quinine.  In conclusion, P. 
falciparum remains the main species responsible for imported malaria in Milan, Italy, with VFRs 
and first arrival migrants being at the highest  risk. P. vivax malaria was diagnosed in the majority 
of cases in asylum seekers from Eritrea. The use of chemoprophylaxis is still negligible among 
subjects at higher risk of developing malaria. Early and accurate diagnosis with prompt treatment of 
clinical malaria are essential for reducing malaria morbidity and mortality. 
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Table 1- Summary of recent studies regarding imported malaria in Europe 
 
Author, reference Rey, 3 Antinori, 2 Stepien, 6 Fernandez 
Lopez, 4 
Francis, 5 Modol, 7 Luise, 8 Zanotti, 9 Calderaro, 10 
City, Country Madrid, Spain Milan, Italy Poland Madrid, Spain London, United 
Kingdom 
Barcelona, 
Spain 
Padua, Italy Brescia,Italy Parma,Italy 
Period of study 2005-2008 1998-2007 2003-2011 2004-2014 2013-2015 2007-2016 2005-2015 1999-2016 2013-2017 
Type of the study Retrospective, 
single center 
Retrospective, 
single center 
National 
surveillance 
Retrospective, 
single center 
Retrospective, 
single center 
Prospective 
observational, 
multicenter 
Retrospective, 
single center 
Retrospective, 
single center 
Prospective 
observational
, single 
center 
N° patients 57 291 189 185 133 190 124§ 975§ 69§ 
Male sex (%) 24 (42.1%) 186 (64%) 139 (74%) Not reported 86 (64.7%) 121 (63.7%) 90 (72.6%) 742 (76.1%) 66 (74.2%) 
Age (years), median 27.8* 35  36 30.8* 41 32* 39 37.8* Not reported 
Species of Plasmodium 
- P. falciparum 
- P. vivax 
- P. ovale 
- P. malariae 
- Coinfections 
- Unknown 
 
 
54 (94.7%) 
- 
3  (5.3%) 
- 
- 
- 
 
228 (78.3%) 
 48 (16.5%) 
  9  (3.1%) 
  1 (0.3%) 
  5 (1.7%) 
  - 
 
115 (60.8%) 
  35 (18.5%) 
    3 (1.6%) 
    3 (1.6%) 
    6 (3.2%) 
  27 (14.3%) 
 
167 (90.3%) 
   3  (1.6%) 
   3  (1.6%) 
   3  (1.1%) 
   6  (3.2%) 
   - 
 
102 (76.7%) 
 23  (17.3%) 
  3  (2.3%) 
  2  (1.5%) 
  3  (2.3%) 
 - 
 
122 (64.2%) 
 44  (23.2%) 
  2   (1.1%) 
  3   (1.6%) 
  5  (2.6%) 
14 (7.4%) 
 
110 (88.8%) 
  6   (4.8%) 
  0   (0%) 
  3   (2.4%) 
  2   (1.6%) 
  3  (2.4%)   
 
820 (84.1%) 
 96 (9.8%) 
 37 (3.8%) 
 20 (2.1%) 
  2  (0.1%) 
- 
 
58 (84%) 
 2  (2.%) 
 8  (11.6%) 
 1  (1.4%) 
 2  (2.9%) 
 
Chemoprophylaxis 
- Correct 
 
6/55 (10.9%) 
 1/6 (16.7%) 
 
61/258 (23.6%) 
32/61 (52.5%) 
62/189 (33%) 
 6/62 (9.7%) 
29/185 (15.7%) 
  8/29  (27.6%) 
20/79 (25.3%) 
 5/8   (62.5%) 
19/190 (10%) 
  2/19 (10.5%) 
16/104 (15.4%) 
    3/16  (18.7%) 
9/644 (1.4% 
9/644 (1.4%) 
Not reported 
Travel reason 
- Tourism 
- VFR 
- Recent 
immigrant 
- Missionary 
- Business/work 
- Unknown 
 
  2  ( 3.6%) 
34 (61.8%) 
19 (34.5%) 
 
- 
- 
 
146 (50.2%) 
  95 (32.6%) 
  35 (12%) 
 
    5 (1.7%) 
  10 (3.4%) 
 
71 (38%) 
 
13 (7%)^ 
 
- 
66 (35%) 
17 (9%) 
 
- 
159 (85.9%) 
 25 (13.5%) 
 
- 
- 
- 
Not reported  
    8 (4.2%) 
171 (90%) 
- 
- 
 
11 (5.8%) 
- 
 
 
15 (12.1%) 
86 (69.4%) 
 8   (6.4%) 
- 
15 (12.1%) 
- 
- 
 
  40 (4.1%) 
619 (63.5%) 
  97 (9.9%) 
  52 (5.4%) 
  41 (4.2%) 
- 
- 
Not reported 
HIV serology done 
Positive 
20 (35.1%) 
2/20 (10%) 
Not reported Not reported 89/185 (48.1%) 
  8/89   (8.9%) 
36/133 (27.1%) 
 3/36   (8.3%) 
Not reported Not done Not done Not reported 
Positive 
immunochromatography 
42/57 (73.7%) Not done Not reported 11/11 (100%) 52/53  (98.1%) 109/124  
(87.9%) 
Not done Not reported 65/69 
(94.2%) 
Hospital admission 9 (15.8%) 291 (100%) Not reported 176 (95.1%) 107 (91.5%) 127 (66.8%) 124 (100%) Not stated Not stated 
Severe P. falciparum 0 35/233 (15%) 38/118   8/173 (4.6%) 37/102 (36.3%)  34/127 5 (4%) 49/820 (5.9%) Not reported 
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malaria (32.2%) (26.8%) 
Mortality 0 0 5/189 (2.6%) 0 0 0 0 2 (0.2%) 0 
* mean age; ^ Not stated if VFR or recent immigrants; § In all these studies were enclosed also children that are excluded from this analysis 
 
 
 
 
 
 
